Furthermore, the authors found that the inhibition of miR-155 in the antagomir-treated group showed a reduced number of Th17 cells and a decline in IL-17A and IL-6 levels but an increase in Treg cells, IL-10, TGF-B1, in the mesenteric lymph nodes, indicating the maintenance of Th17/Treg cell balance as a strategy to alleviate colitis [117]. This evidence concerns the gene IL17A and colitis.